Drug Discovery & DDS– category –
-
Antibody-Drug Conjugate (ADC) Development Guide: Precise Design of Monoclonal Antibodies, Linkers, and Payloads is Key
Allucent USA Overview Antibody-Drug Conjugates (ADCs) combine three engineered components—a tumor-targeting monoclonal antibody, a chemical linker, and an active payload—to deliver potent cancer therapy. Upon binding to the target, ADCs ... -
Johns Hopkins’ N4-Acetylcytidine (ac4C) mRNA Platform Boosts Therapeutic Protein Production Beyond Industry Standard
Johns Hopkins Medicine USA Overview Scientists at Johns Hopkins Medicine have reported an experimental N4-acetylcytidine (ac4C) mRNA platform capable of delivering next-generation mRNA therapeutics for infectious diseases, cancer, and au... -
Bispecific Antibodies Revolutionize Cancer Therapy: 15 FDA-Approved, Over 600 in Clinical Trials as T-Cell Engagers
BroadPharm USA Overview Bispecific antibodies (BsAbs) are engineered to simultaneously bind two different antigens or epitopes, offering superior disease target recognition and biological effect modulation compared to conventional monocl... -
AI Transforms Drug Discovery: Machine Learning Drastically Cuts Costs & Timelines, Yields 75 Clinical Candidates
Facebook USA Overview AI is accelerating drug discovery and significantly reducing costs by leveraging machine learning to design candidate molecules and drastically narrow the vast protein structure search space. Algorithms like generat... -
AI Accelerates Drug Discovery: AlphaFold, Generative Models Drive R&D Efficiency & Clinical Pipeline Growth
Markets Insider USA Overview AI has dramatically accelerated drug discovery over the past five years through advancements in protein structure prediction, generative chemistry, and phenotypic screening. Tools like DeepMind's AlphaFold ha... -
Drug Discovery & DDS Weekly Report August 22, 2026
▼ ▼ ▼ If the infographic makes you want to read the full report, please click the download button below. ▼ ▼ ▼ 📄 Weekly Report August 22, 2026 (PDF) — Download Weekly Report August 22, 2026 (PDF) — DownloadDownload 🎙 Podcast August 22, ... -
PitchBook Analysis: Rebounding Biotech Funding Expected to Drive CDMO Growth in 2026, Focus on Complex Modalities
BioSpace USA Overview This article provides an overview of a PitchBook analysis report. According to PitchBook, biotech venture capital funding in the first half of 2026 surpassed $10 billion, driven significantly by Isomorphic Labs' $2.... -
Biotech VC Funding Reaches $20.1 Billion in H1 2026 as Companies Secure Significant Capital for Early Development Stages
BioBucks / Fierce Biotech USA Overview In the first half of 2026, biotech VC funding totaled $20.1 billion, with several companies completing major financing rounds. Vaderis Therapeutics secured $152 million in Series B for a Phase III t... -
K-38 Consulting Report: Biotech VC Funding Rebounds to Over $9.1 Billion in H1 2026, While Early-Stage Investment Hits Pre-Pandemic Low
WBOC (Press Release) USA Overview This article presents an overview of a market research report by K-38 Consulting. The report indicates that biotech venture capital funding in the first half of 2026 exceeded $9.1 billion, reaching its h... -
DCAT Report: 2026 CDMO Market Sees Major M&A and Capital Investments, with Samsung Biologics to Acquire PolyPeptide Group for $1.8 Billion
DCAT Value Chain Insights USA Overview According to a DCAT Value Chain Insights report, the 2026 CDMO market is witnessing a surge in peptide-based drug development, accompanied by significant M&A and capital investments. Samsung Bio...
